Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what estimate he has made of when Tolvaptan will be available through the NHS to treat autosomal dominant polycystic kidney disease.

Tolvaptan (Jinarc) became available through the National Health Service following its launch in the United Kingdom in June 2015.

In October, the National Institute for Health and Care Excellence (NICE) published technology appraisal guidance recommending tolvaptan as a treatment for autosomal dominant polycystic kidney disease where certain conditions are met.

NHS commissioners are legally required to fund drugs and treatments recommended by NICE technology appraisals within three months of the NICE technology appraisal guidance being published.